Podcasts about Moravec

Ömer ve Yaşar Ateş Ölçer'in yepyeni bölümünde Dreame Ev Robotları sponsorluğunda istihdam krizini ve yapay zekayının geleceğe etkilerini tartışıyor!2025 yılı içerisinde sık sık haberlerde karşılaştığımız işten çıkarma haberlerinden yola çıkarak yeni mezunlara açılan işlerde azalmayı, beyaz yaka işlerdeki daralmayı, otomasyona kurban giden işleri ve yapay zekanın yeni işler yaratıp yaratamayacağını değerlendiriyorlar. Sadece istihdam ve ekonomi ile sınırlı kalmayan tartışma kapitalizmin doğası ve geleceğin siyasi sistemlerine dair bir beyin fırtınasına da ilerliyor.00:00 - Giriş01:27 - İşten çıkarma trendi06:25- Büyük teknoloji şirketleri kapitalizme etkisi08:38 - Yapay zekanın beyaz yaka işlere etkisi12:03 - Yapay zekanın istihdama etkisi16:00 - Moravec paradoksu17:25 - Dreame Ev Robotu18:50 - Diplomanın öneminin zayıflaması23:50 - Yapay zekanın becerilerinin hızlı gelişimi25:27 - Jevons paradoksu28:20 - Yapay zeka mevcut toplumu nasıl etkileyecek?30:45 - Ev genci krizi32:18 - Türkiye'de istihdamın geleceği36:50 - Kamu istihdamı öne mi çıkacak?41:08 - Büyük güç mücadelesinin teknoloji yarışına etkisi44:00 - Demokrasinin sonu mu geliyor?48:12 - Verimliliği tekrar düşünmek51:10 - Kapanış

You’ve probably heard the words ‘biofeedback' and ‘neurofeedback' floating around the internet. And you're also probably wondering what they mean and if they're worth your time and money when you have a vestibular disorder. I'm answering all of that in this episode! Biofeedback is a type of mind-body technique to control some of the body's function. And neurofeedback is a type of biofeedback that measures and records brainwaves. As always, I've got research and scenarios for us to talk through to help this really land. They're probably not the first thing you want to invest in and there are even less expensive options that are equally or more effective which I share more about in the episode. Buckle up and let's get a little nerdy with this one! In this episode, we'll dig into: What biofeedback is and how it works What the main types of biofeedback are What neurofeedback is and how it relates to biofeedback The difference between active and passive neurofeedback The two main models of biofeedback that exist What to expect in a biofeedback session What biofeedback is considered effective for Types of neurofeedback and biofeedback sessions, devices, and apps available How to find a qualified biofeedback provider What questions to ask before committing to either option If you want to go even deeper with what you heard in this episode, we have coaching calls specifically about biofeedback and neurofeedback available in Vestibular Group Fit. Biofeedback is a tool, not a cure. But if you’re curious, informed, and financially comfortable exploring it, it absolutely can have a place in your vestibular toolkit. Links Mentioned: Vestibular Group Fit (code GROUNDED at checkout for 15% off!): https://thevertigodoctor.com/vestibular-group-fit Certification from the Association for Applied Psychophysiology and Biofeedback (AAPB) site has an option to find a practitioner: https://aapb.org/Find_a_Practitioner  Hearthmath: https://www.heartmath.com/  Resperate (FDA approved for blood pressure and stress): https://resperate.com  Leva (FDA approved for pelvic floor): https://levacares.com/  Prism (FDA approved for PTSD): https://www.graymatters-health.com/prism-for-ptsd  Finding a provider International society for neuroregulation and research: https://isnr.org/ Biofeedback certification international alliance: https://www.bcia.org/ Free Resources: ⁠The 4 Steps to Managing Vestibular Migraine: https://thevertigodoctor.myflodesk.com/cb5js0y78n ⁠The PPPD Management Masterclass⁠: https://thevertigodoctor.myflodesk.com/new-pppd ⁠What your Partner Should Know About Living with Dizziness⁠: https://thevertigodoctor.myflodesk.com/partnership ⁠The FREE Mini VGFit Workout⁠: https://thevertigodoctor.myflodesk.com/minifit ⁠The FREE POTS – safe Workouts⁠: https://thevertigodoctor.myflodesk.com/pots Connect with Dr. Madison (@TheVertigoDoctor): https://instagram.com/thevertigodoctor Work with Dr. Madison: For 1:1 Vestibular Rehabilitation Therapy, email madison@thevertigodoctor.com Otherwise, I'll see ya in Vestibular Group Fit! Connect with Dr. Jenna (@dizzy.rehab.therapist): https://www.instagram.com/dizzy.rehab.therapist/ Learn about the Oak Method: http://thevertigodoctor.com/why-vestibular-group-fit Love what you heard?Consider leaving a review on your favorite podcast platform to help us reach more vestibular warriors like you! This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. Citations Frank, D. L., Khorshid, L., Kiffer, J. F., Moravec, C. S., & McKee, M. G. (2010). Biofeedback in medicine: who, when, why and how?. Mental health in family medicine, 7(2), 85–91. Mayo Clinic. “Biofeedback – Mayo Clinic.” Mayoclinic.org, 18 Mar. 2023, www.mayoclinic.org/tests-procedures/biofeedback/about/pac-20384664. Marzbani, H., Marateb, H. R., & Mansourian, M. (2016). Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic and clinical neuroscience, 7(2), 143–158. https://doi.org/10.15412/J.BCN.03070208 Bazzana, F., Finzi, S., Di Fini, G., & Veglia, F. (2022). Infra-Low Frequency Neurofeedback: A Systematic Mixed Studies Review. Frontiers in human neuroscience, 16, 920659. https://doi.org/10.3389/fnhum.2022.920659 Duke, G., Yotter, C. N., Sharifian, B., Duke, G., & Petersen, S. (2024). The effectiveness of microcurrent neurofeedback on depression, anxiety, post-traumatic stress disorder, and quality of life. Journal of the American Association of Nurse Practitioners, 36(2), 100–109. https://doi.org/10.1097/JXX.0000000000000945 Cleveland Clinic. “Biofeedback: What Is It & Procedure Details.” Cleveland Clinic, 21 Dec. 2020, my.clevelandclinic.org/health/treatments/13354-biofeedback. biofeedback and neurofeedback, biofeedback vs neurofeedback, vestibular group fit, VGF, vestibular disorders, chronic dizziness, PPPD, nervous system regulation, migraine management, stress relief, alternative therapies, holistic approach, living with vestibular migraine, living with vertigo, migraine toolkit, vestibular disorder treatment

V neděli v poledne se v Česku neděje jen oběd. Děje se politika. A podle Jindřicha Šídla je právě tahle posedlost debatami, glosami, slogany a televizními duely jednou z věcí, které nás jako zemi docela přesně vystihují.V Koťák Live mluví o tom, proč ho politika baví už od devadesátek, jak vzniká politická satira a proč nestačí jen říct, že politici jsou směšní. Skutečná výzva je najít přesný vtip. Třeba na Petra Fialu, u kterého je to podle Šídla překvapivě těžká disciplína.Nejsilnější část přichází u Andreje Babiše. Po koupi vydavatelství MAFRA měl Šídlo dostat nabídku stát se šéfredaktorem Mladé fronty DNES. Odmítl ji a záměrně si nenechal říct, kolik by za to dostal. Jak sám vysvětluje, nechtěl, aby peníze začaly přebíjet zásady.A pak už je to jedno politické peklo: Chuck Norris, Walker Texas Ranger, modrá knížka, Václav Moravec, Miloš Zeman v Zemáku, Becherovka, martini, Kalouskovy básně a otázka, kde končí vtipný politik a začíná politik směšný.

Na podzim 1941 se Reinhard Heydrich ujal funkce zastupujícího říšského protektora. S jeho příchodem dopadl na české obyvatelstvo teror, ale pro Emanuela Moravce začala zlatá éra. V lednu 1942 se stal ministrem školství a národní osvěty. Pro nacisty byl ideálním mužem, protože potřebovali někoho, koho se bude bát i protektorátní vláda.

Co obsahuje memorandum o porozumění mezi Spojenými státy a Íránem, které má otevřít cestu k mírové dohodě? Proč chtějí Spojené státy přezkoumat přítomnost svých vojsk v Evropě? A co znamená zvolení Petra Moravce do čela Správy Krkonošského národního parku?

Co obsahuje memorandum o porozumění mezi Spojenými státy a Íránem, které má otevřít cestu k mírové dohodě? Proč chtějí Spojené státy přezkoumat přítomnost svých vojsk v Evropě? A co znamená zvolení Petra Moravce do čela Správy Krkonošského národního parku?

Co obsahuje memorandum o porozumění mezi Spojenými státy a Íránem, které má otevřít cestu k mírové dohodě? Proč chtějí Spojené státy přezkoumat přítomnost svých vojsk v Evropě? A co znamená zvolení Petra Moravce do čela Správy Krkonošského národního parku?Všechny díly podcastu Hlavní zprávy - rozhovory a komentáře můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Je málo jmen, která jsou tak úzce spojena se zradou, jako jméno někdejšího protektorátního ministra školství a národní osvěty Emanuela Moravce. Muže, který byl za první republiky podporovatelem Tomáše G. Masaryka a jeho hradní skupiny. Muže, který byl jedním z nejzarputilejších odpůrců přijetí mnichovského diktátu. Muže, ze kterého se ale nakonec stal kolaborant a poskok nacistů.

Václav Moravec a jeho start bez zázemí České televize otevírá hned několik zásadních otázek. Může uspět ve světě podcastů a předplatného, když sází na stará pravidla úplně jiné hry? Pochopil, že podcasty nejsou televize? Dnes nás také čeká zásadní hlasování o metropolitním plánu, který může rozhodnout o budoucnosti Prahy a odemknout výstavbu až statisíců bytů. Kdo plán podpoří a kdo skončí na tabuli hanby? Co stojí za prodejem Explosie a proč stát pouští z ruky strategickou firmu právě teď? Kdo z ministrů je pod tlakem a chystá se první větší rošáda ve vládě?Partnerem podcastu je advokátní kancelář ROWAN LEGAL a mezinárodní poradenská společnost RSM

Did you know that Pinterest is the BEST free tool that Etsy sellers can leverage to send tons of traffic to their listings? Emily is a Pinterest for Etsy expert who created over 13,000 personal Etsy sales using the power of Pinterest. Tune in to hear her tips, story, and strategy that can level up your Etsy success to new heights with 3 months of focused, consistent effort.  **"How to Sell Your Stuff on Etsy" is not affiliated with or endorsed by Etsy.com    STUFF I MENTIONED:  Join Scaling Society: https://www.howtosellyourstuff.com/scaling-society  SPECIAL DISCOUNT:  Get $50 off your first month with code EMILY50   Try Everbee Free:  https://www.everbee.io/?via=lizzie   Emily's last episode: #181 $3k per month on Etsy with Digital Exercise Guides --with Emily Moravec:  https://www.howtosellyourstuff.com/blog/181    Hanna's Episode (very niche: tea kits): #227: Squirrel Syndrome Can Lead to Massive (Repeated) Etsy Success -with Hanna McComish: https://www.howtosellyourstuff.com/blog/227    Alex's Episode (sensory kits– drove her own traffic): #222: How Driving Her Own Traffic Sparked Faster Organic Etsy Sales - with Alex Chavez https://www.howtosellyourstuff.com/blog/222    FIND EMILY: @emmypins    HOW I HELP ETSY SELLERS GROW: ⭐Scaling Society: https://www.howtosellyourstuff.com/scaling-society ⭐"How to Blow Up Your Etsy Shop" free training: https://www.howtosellyourstuff.com/interested-in-blow-up-shop  ⭐Trendspotting: https://www.howtosellyourstuff.com/trendspotting ----------------------

Petr Moravec je zasloužilým dárcem krve. S bannerem, na kterém má uvedený počet svých odběrů, vystoupil na nejvyšší horu Ameriky. Poslechněte si rozhovor o životě dárce i o zážitku z výstupu na vrchol.Všechny díly podcastu Host Českého rozhlasu Ostrava můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

This and all episodes at: https://aiandyou.net/ . AI abounds with paradoxes.  I have been talking about those with Virginia Dignum, professor of responsible artificial intelligence at Umeå (OOMEO) university, about her new book, The AI Paradox: How to Make Sense of a Complex Future, just released, with links in the show notes and transcript. Virginia is an internationally recognized expert in AI ethics and policy who has led initiatives for the European Commission, the United Nations, the World Economic Forum, UNESCO, and UNICEF, among others, and is the author of the 2019 book Responsible Artificial Intelligence. We conclude the interview by talking about some paradoxes in detail, like Moravec's Paradox, questions about using AI in legal decisions, AI literacy, and the recent battle between Anthropic and the US Department of Defense, and OpenClaw. All this plus our usual look at today's AI headlines! Transcript and URLs referenced at HumanCusp Blog.        

Welcome to PGX Ideas.PGX Ideas is where I sit with people who think for a living — scientists, philosophers, builders, and the occasional genius who doesn't fit any category.These conversations are dense. They're long. They won't give you a shortcut.If you're looking for something light, that's PGX: Raw & Real → https://www.youtube.com/playlist?list=PLa6DgTttATAc0hftp0aZtUvCgVSKO8hbxIn this episode, I spoke to Varun Mayya — Media Entrepreneur.Timestamps:00:00 - Start01:06 - Where are we in the AI story right now?01:36 - Jobs are JUST 300 years old04:00 - If AI replaces humans, who pays for stuff???07:00 - Mind reading technology10:00 - Cameras changed human psychology and social behavior13:00 - Elon and X17:43 - Is AGI here?18:21 - Varun's conversation with Demis Hassabis (Google DeepMind)19:11 - Can AGI be better than Einstein?20:12 - Moravec's paradox and why computer use is harder than chess21:10 - Embodied AGI and robotics — why it's 10-Moravec'saway26:00 - Why human intelligence is fundamentally emotional28:05 - Theory of mind — do LLMs actually have it?28:25 - Why Varun won't give AI rights yet33:00 - Does AI show signs of self-preservation and agency?34:00 - Stanford Pokemon experiment36:00 - AIs developing their own language!!!48:00 - Students would pay to leave TikTok55:33 - Varun's business model explained57:00 - How to create millions of views?01:01:00 - The storyteller eats the world01:03:00 - Shah Rukh Khan, PR seeding and suspended reality01:07:00 - The Facebook poke button01:17:00 - We made a mistake connecting identity to work01:20:00 - Why office politics is good01:26:00 - What do people do when work disappears01:35:45 - Varun at the PM office01:43:00 - Bangalore Police using AI for 112 calls01:43:44 - Varun's advice for the 99% whose jobs are at risk01:50:00 - Indians complain too much01:51:36 - Varun's identity reset after selling his last company01:57:00 - India should learn from ChinaEnjoy.— Prakhar_________________________________________________________________________________________________Watch NextFor more ideas, insight, and perspective → https://www.youtube.com/playlist?list=PLa6DgTttATAcNdrNSG8Hh78TK-5A0EJbCIf you're looking for human stories & emotion, go to PGX: Raw & Real → https://www.youtube.com/playlist?list=PLa6DgTttATAc0hftp0aZtUvCgVSKO8hbx_________________________________________________________________________________________________Learn with MeMaster the art of Conversation → https://www.artofconversation.in/_________________________________________________________________________________________________Guest - Varun MayyaInstagram: https://www.instagram.com/thevarunmayyaX: https://x.com/waitin4agi_YouTube:  @VarunMayya  LinkedIn : https://in.linkedin.com/in/varunmayya_________________________________________________________________________________________________TeamHost — Prakhar GuptaProduced by — Ansh Bhatnagar and Govind Vashistha_________________________________________________________________________________________________Contact usLooking to join our team? → govind@thepravachan.com (Govind Vashistha)For business related queries → contact@thepravachan.com_________________________________________________________________________________________________PGX SocialsInstagram → https://www.instagram.com/pgxpodcast/X (Twitter) → https://twitter.com/pgxpodcastLinkedIn → https://www.linkedin.com/in/prvkhvr/Main Channel → https://www.youtube.com/@prakharguptaClips Channel → https://www.youtube.com/@PGXClips_________________________________________________________________________________________________Follow meTwitter: https://twitter.com/prvkhvrInstagram: https://www.instagram.com/prvkhvr/LinkedIn: https://www.linkedin.com/in/prvkhvr/

Závěr březnové "šňůrky" v plzeňské Moving Station odkryl pozadí chystaného zákona proti neziskovkám, jehož metadata nesou ruskou stopu a přímé vazby na Babišovu poradkyni Natálii Vachatovou. Zatímco Sněmovna tráví časb„dnem krojů“ a Václav Moravec definitivně opouští Českou televizi, hrozí nová legislativa likvidací klíčových sociálních a zdravotních služeb. Mezinárodní scénu mezitím drtí Putinovo ovlivňování maďarských voleb, nebezpečná shoda v rétorice Trumpa a Putina v íránském chaosu i nová jaderná doktrína Francie, kterou doplňuje fascinující vědecký pokrok projektu CETI při statistickém dekódování jazyka velryb.Celé epizody na https://www.herohero.co/kanarcivsiti . A nebo si kupte naše trička na https://www.neverenough.shop/kanarci . Podcast pro Vás připravují @alexalvarova a @holyj . Hudba a sound engineering: PsyekTwitter Spaces moderuje @jiribulan .Najdete nás na www.kanarci.online

CELÝ ROZHOVOR V DÉLCE 59 MIN. JEN NA ⁠HTTPS://HEROHERO.CO/CESTMIR⁠⁠⁠⁠ A ⁠HTTPS://FORENDORS.CZ/CESTMIR „Je strašně těžké bojovat s tímhle skoro až barvotiskovým příběhem o tom, že odcházejí jediní spravedliví a zůstávají jen ti, kteří mají zlomenou páteř,“ říká šéf zpravodajství a publicistiky České televize Michal Kubal, když vysvětluje bouři kolem odchodu Václava Moravce. Podle něj se kolem České televize vytvořil jednoduchý a přitažlivý narativ o úpadku veřejnoprávního média, se kterým je ale obtížné polemizovat. V rozhovoru se vrací k tomu, co předcházelo Moravcovu konci v Otázkách Václava Moravce a k debatě o pozvání Tomia Okamury. Spor podle něj nebyl o redakční nezávislost, ale o dlouhodobě neřešený problém. „Jediný problém, který jsem kdy měl s Václavem Moravcem, byla kauza Okamura,“ říká Kubal a připomíná, že předseda parlamentní strany osm let v pořadu nevystoupil. Podle něj přitom není jisté, že to byla nevýhoda pro Okamuru - naopak mohl uniknout tvrdé konfrontaci. „Není to vlastně výhoda pro Tomia Okamuru, že osm let nečelil jednomu z nejlepších politických moderátorů?“ ptá se. Kubal zároveň odmítá argument, že pozvání Okamury bylo kapitulací před politickým tlakem. Podle něj se z problému stal symbol až ve chvíli, kdy byl dlouho odkládán. Přirovnává to k absurdní situaci: jako kdyby někdo osm let „přifukoval balónek“ tím, že jednoho politika do pořadu nezve, a pak ho odmítl pozvat právě proto, že je kolem něj najednou příliš velký balon. Jinými slovy - problém podle něj vznikl spíš tím, že se léta neřešil. Moravcovo rozloučení na obrazovce ho podle vlastních slov překvapilo. „Měl jsem naivní představu,“ říká dnes. A zároveň dodává, že způsob, jakým moderátor odešel, považuje za problém i vůči kolegům: „To, co se odehrálo v neděli ve dvě hodiny, pro mě byl jeden obrovský výtrysk ega a pošpinění práce stovek lidí.“ Celá debata navíc přichází v době, kdy se znovu řeší samotná budoucnost veřejnoprávních médií a jejich financování. Politici mluví o zrušení koncesionářských poplatků a o modelu financování ze státního rozpočtu. Kubal připouští, že změna je možná, ale varuje před riziky. „Mělo by to být maximálně odříznuté od politického vlivu na to, kolik peněz jednotlivé instituce dostanou,“ říká a dodává, že by politici neměli rozhodovat každý rok o financování médií veřejné služby. „Aby nás nedrželi pod krkem a neříkali: ty ty ty, vy jste zlobili v těch reportérech a už žádné reportáže o STBácích. A nebo aby to na začátku nebylo podseknuté tak, že ty instituce dřív nebo později prostě umřou na úbytě,“ varuje. Je Česká televize skutečně pod politickým tlakem, nebo jde jen o silný mediální příběh? Byl spor o Tomia Okamuru symbolem ztráty redakční nezávislosti, jak tvrdí Václav Moravec, nebo jen dlouho odkládaným problémem? A může debata o financování veřejnoprávních médií rozhodnout o tom, jak budou vypadat v budoucnu? I o tom je rozhovor s Michalem Kubalem.

Daniela Bombica uznal špecializovaný súd za vinného, Slovensko oficiálne odmietne nové medzinárodné zdravotnícke predpisy WHO, prezident Peter Pellegrini sa tento týždeň ukázal na dvoch tlačových konferenciách s koalíciou a premiérom Ficom, český moderátor Václav Moravec končí po 21 rokoch v ČT a hovorí, že v aktuálnom stave už nemôže garantovať nezávislosť redakčnej práce. Sobotným Dobrým ránom vás sprevádzajú Zuzana Kovačič Hanzelová a Jakub Filo. Otázky do nasledujúcej epizódy Dobrého rána sobota nám zasielajte na e-mail dobrerano@sme.sk, ideálne vo forme hlasovej správy. Do predmetu napíšte Otázka do sobotného Dobrého rána. Zdroje zvukov: Youtube/TA3, Youtube/ajjateba, 360tka, Youtube/360tka, STVR, Česká televize, TA3, Youtube/SMER - Sociálna Demokracia – Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifingSee omnystudio.com/listener for privacy information.

Jak s odstupem hodnotí svůj krok? Bylo to fér ke kolegům a k ČT? A kdy a kde se chce vrátit k novinářské práci? Moderuje Tomáš Pancíř.

„Patří k žurnalistice, že máte fakta, máte relevanci a nemůžete se podle mého názoru, pokud ten pořad chcete dělat úspěšně, chcete ho dělat pro diváky, dostat pouze do čárkovací pozice,“ říká novinář a pedagog Václav Moravec, který oznámením v živém vysílání ukončil své 21leté působení v České televizi. Jak s odstupem hodnotí svůj krok? Bylo to fér k jeho kolegům a ČT? A kdy a kde se chce vrátit k novinářské práci? Poslechněte si rozhovor.Všechny díly podcastu Dvacet minut Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

CELÝ ROZHOVOR NAJDETE NA HEROHERO.CO/STUDION „Čeká mě teď s mými právníky jedna věc – budu posílat zpátky do České televize peníze, abych se vyvázal z konkurenční doložky,“ říká ve Studiu N moderátor Václav Moravec. V rozhovoru s Filipem Titlbachem reaguje i na kritiku kolegů a kolegyň z Kavčích hor: „Neřekl jsem, že jsou tam zcenzurované ovce, to bych si vůči kolegům v životě nedovolil. Ale že se sami adaptují na prostředí, ve kterém už se já necítím dobře.“ Management zpravodajství podle něj počítal s tím, že do vysílání s Tomiem Okamurou vůbec nedorazí. „Myslím si, že se většina redakce domnívala, že využiju klauzuli svědomí. Michal Kubal v rozhovoru pro Seznam Zprávy řekl, že Moravec má osobní problém s Okamurou – to byla lež –, a že pokud využiju klauzuli svědomí, budu se na tom pořadu s někým střídat. Oni počítali s tím, že budou hrát příběh mé neprofesionality a egomaniactví,“ tvrdí moderátor. O tom, že se chystá v závěru pořadu oznámit svůj konec v České televizi, věděli na place jen dva lidé. „Nechtěl jsem znervóznit štáb,“ říká Moravec. „Nevěděl jsem, jaký bude Tomio Okamura, ale musím říct, že mě překvapil. Dovolím si říct, že jsme byli oba nervózní. Je fakt skvělý, protože ukázal ostatním politikům cestu, jak dál zraňovat a dostávat do defenzivy médium veřejné služby.“ Moravec ve Studiu N tvrdí, že je překvapený z toho, jak jeho konec zaskočil vedení redakce. „Počítali s tím. Michal Kubal říkal, že když Moravec odmítne, mají připraveného jiného moderátora. Jak mohli být zaskočeni?“ Proč si přinesl na vysílání s Tomiem Okamurou svou výplatní pásku? Co mu napsal půl hodiny po posledních Otázkách expremiér Mirek Topolánek? A neměl odejít už dříve? Podívejte se na celý rozhovor na herohero.co/studion

Česká televize dál řeší, jak a kým nahradit nedělní diskuzní pořad Otázky Václava Moravce. Moravec totiž v poslední živé relaci oznámil, že z televize odchází. Za současných podmínek prý nemůže dál zaručit nezávislost redakční práce a kritickou reflexi podle veřejnoprávního kodexu. Prozatímně mají podle informací Seznam Zpráv Otázky Václava Moravce nahradit Události, komentáře speciál. Co reakce kolem Moravcova odchodu vypovídá o stavu České televize jako celku? Host: Jan Motal - Vedoucí Centra pro mediální etiku a dialog na katedře mediálních studií a žurnalistiky na Masarykově univerzitě v Brně Článek a další informace najdete na webu Seznam Zprávy. Sledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz

Česká televize dál řeší, jak a kým nahradit nedělní diskuzní pořad Otázky Václava Moravce. Moravec totiž v poslední živé relaci oznámil, že z televize odchází. Za současných podmínek prý nemůže dál zaručit nezávislost redakční práce a kritickou reflexi podle veřejnoprávního kodexu. Prozatímně mají podle informací Seznam Zpráv Otázky Václava Moravce nahradit Události, komentáře speciál. Co reakce kolem Moravcova odchodu vypovídá o stavu České televize jako celku?Host: Jan Motal - Vedoucí Centra pro mediální etiku a dialog na katedře mediálních studií a žurnalistiky na Masarykově univerzitě v BrněČlánek a další informace najdete na webu Seznam ZprávySledujte nás na sociálních sítích X, Instagram, Threads nebo Bluesky. Náměty a připomínky nám můžete psát na e-mail zaminutusest@sz.cz

Česká televize se vyrovnává s odchodem svého nejvýraznějšího moderátora politických debat. Václav Moravec končí v ČT po více než 21 letech. Jeho nedělní Otázky dočasně nahradí speciál Událostí, komentářů. Kam Moravec zamíří?Hostem Ptám se já byl moderátor Václav Moravec. Ten oznámil odchod z České televize v neděli na závěr živého vysílání svého pořadu Otázky Václava Moravce (OVM). Rozhodl se tak poté, co nová dramaturgyně přes jeho nesouhlas pozvala šéfa SPD a předsedu Poslanecké sněmovny Tomia Okamuru. Moderátor uvedl, že za současných podmínek už nemůže dál garantovat nezávislost redakční práce.„Děje z poslední doby mne utvrdily v tom, že za současných podmínek už nemohu dál garantovat nezávislost redakční práce a kritickou reflexi událostí, jak se o nich zmiňuje preambule kodexu ČT,“ uvedl. A dodal, že nechce zklamávat důvěru diváků nejsledovanějšího nedělního diskuzního pořadu „posunem k pseudovyváženosti, chcete-li, ke slepé vyváženosti“. Ta podle jeho názoru ničí veřejnou službu.Způsob, kterým Moravec svůj konec ohlásil, podle vedení ČT nebyl šťastný. Televize zároveň odmítla zpochybnění své nezávislosti. Svůj možný odchod naznačil moderátor už počátkem roku v souvislosti s tehdejšími diskuzemi o vyváženosti Otázek v souvislosti s tím, že do pořadu nebyl devět let zván právě Tomio Okamura. Vedení televize kvůli tomu koncem ledna odstavilo dlouholetou hlavní dramaturgyni pořadu Hanu Andělovou. ČT dnes informovala, že Moravec v úterý ukončil svůj pracovní poměr dohodou. S televizí má sjednanou konkurenční doložku, která na půl roku omezuje jeho působení v jiných médiích. Jak popsaly i Seznam Zprávy, namísto OVM bude Česká televize v neděli ve 12 hodin dočasně vysílat pořad Události, komentáře speciál. Nepoškodil Václav Moravec Českou televizi? A stálo mu nezvaní Tomia Okamury za to?--Podcast Ptám se já. Rozhovory s lidmi, kteří mají vliv, odpovědnost, informace.Sledujte na Seznam Zprávách, poslouchejte na Podcasty.cz a ve všech podcastových aplikacích.Archiv všech dílů najdete tady. Své postřehy, připomínky nebo tipy nám pište prostřednictvím sociálních sítí pod hashtagem #ptamseja nebo na e-mail: audio@sz.cz.

Z Českej televízie odchádza legenda. Václav Moravec, ktorý 21 rokov každé nedeľné poludnie vysielal svoje Otázky Václava Moravce, ohlásil koniec vo verejnoprávnom médiu z dôvodu, ktorý silno pripomína slovenskú mediálnu realitu. Hovorí o tom, že už nevie zaručiť nezávislosť redakcie a v televízii sa – ako u nás – objavujú snahy o umelé vyvažovanie. Čo sa deje vo verejnoprávnej Českej televízii, ako sa to týka predsedu SPD Tomia Okamuru a v čom sa situácia podobá slovenským mediálnym udalostiam, komentuje v podcaste Dobré ráno s moderátorkou Janou Krescanko Dibákovou český komentátor Jindřich Šídlo. Zdroje zvukov: ČT Odporúčanie: Dnes vám chcem trošku netradične odporučiť víkendové instagramové video Vedátora Samuela Kováčika k Medzinárodnému dňu žien. Absolútne skvelo opisuje, ako sme pri ženách a ich možnostiach trochu zabudli na mnohých mladých mužov, ktorí sa pri úspešných ženách strácajú v tom, aká je ich úloha v spoločnosti alebo čo sa od nich očakáva, a z toho pramenia niektoré spoločenské problémy. Dôležité posolstvo na zamyslenie. – Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifingSee omnystudio.com/listener for privacy information.

V Teheráne pršala rozriedená nafta. Českú televíziu po 21 rokoch opúšťa rešpektovaný moderátor Václav Moravec. Kaliňák – jednotka klamárstva.

Jak silnou mocenskou základnu má nově jmenovaný duchovní vůdce Íránu Modžtaba Chameneí? Měly by být v českých školách zakázány, nebo výrazně regulovány mobilní telefony? A jak se k odchodu moderátora Václava Moravce z České televize staví její rada?

Jak silnou mocenskou základnu má nově jmenovaný duchovní vůdce Íránu Modžtaba Chameneí? Měly by být v českých školách zakázány, nebo výrazně regulovány mobilní telefony? A jak se k odchodu moderátora Václava Moravce z České televize staví její rada? Všechny díly podcastu Hlavní zprávy - rozhovory a komentáře můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Aktuální dění kauz zakrývá skutečné průšvihy nejen na ministerstvu financí. Porušila vláda zákon o rozpočtové odpovědnosti, nebo jen ohýbá jeho výklad? A co důchodový systém, který se pravděpodobně znovu stane časovanou bombou? Proč se škrtá na obraně přesně ve chvíli, kdy bezpečnostní rizika rostou? Jaký chaos vzniká kolem podpory OZE, akceleračních zón a Nové zelené úsporám? Jak je to s bojem Filipa Turka proti větrníkům? Odchází Václav Moravec na HeroHero? A sledujeme skutečně demonstrace podobné roku 89?Vstupenky na MASHUP 2026: https://goout.net/cs/listky/mashup-2026-novy-svet-x-insider-x-bruselsky-diktat/xeljb/Dotazník k přihlášení do Young Guns: https://nwcmrs.typeform.com/to/SqPklp00 ⁠⁠⁠⁠Partnerem podcastu je advokátní kancelář ROWAN LEGAL a mezinárodní poradenská společnost RSM.

CELÝ ROZHOVOR V DÉLCE 72 MIN. JEN NA ⁠HTTPS://HEROHERO.CO/CESTMIR⁠⁠⁠⁠ A ⁠HTTPS://FORENDORS.CZ/CESTMIR „Tomia Okamuru považuji za geniálního politika. Ukazuje slabiny systému a ztrátu novinářské autonomie,“ říká moderátor a tvář České televize Václav Moravec a hned tím otevírá téma, které se v rozhovoru neustále vrací: otázku, kdo dnes ve skutečnosti řídí veřejnoprávní média a kde končí redakční autonomie novinářů. Mluví o tom, že spor kolem zvaní Tomia Okamury do Otázek Václava Moravce pro něj není osobní, ale systémový. „Příběh Tomia Okamury je příběhem obecnějším. To je spor o redakční autonomii, o autonomii žurnalistiky jako takové,“ vysvětluje a popisuje, jak se podle něj postupně prolomují hranice mezi kontrolní rolí Rady ČT a reálným zasahováním do dramaturgie a obsahu. „Žádný jiný politik neudělal to, že by si začal stěžovat přes Radu ČT na frekvenci pozvání,“ dodává moderátor a popisuje, jak snaha o vyváženost vede k systému „čárkování“ účasti jednotlivých zástupců politických stran. Moravec mluví i o odvolání dlouholeté dramaturgyně Hany Andělové, které označuje za profesně absurdní krok. „Vydat tiskovou zprávu, že je neprofesionální, je úplně absurdní,” dodává. V jejím příběhu vidí symbol širšího tlaku na veřejnoprávní média a jejich tvůrce. Moderátor se vrací i k vlastní pozici uvnitř České televize a k tomu, jak se jeho role v posledních letech proměnila. Do osobní roviny vstupuje ve chvíli, kdy popisuje vlastní pozici uvnitř ČT. „Nakonec jsem ta černá ovce, která se dozví, že tady ničí Českou televizi. To je úplně absurdní, protože v těch uplynulých 22 letech jsem dělal to, že jsem se snažil věci vysvětlovat,“ tvrdí Moravec. Přesto o své práci mluví bez hořkosti a s nadhledem: „Je to stejně skvělý flám těch 22 let,“ říká o své profesní dráze, ale vrací se i k pocitu, že každý pořad vysílá „jako by byl poslední“. Do rozhovoru vstupují i širší paralely - zkušenosti z BBC, proměna mediálního prostředí, fragmentace publika, ztráta autority institucí a otázka, zda je ještě možné takový proces zastavit. Kde dnes končí redakční autonomie a začíná politický tlak? Je spor o Tomia Okamuru skutečně jen zástupným symbolem hlubší systémové krize? Kdo má dnes reálně moc nad veřejnoprávními médii - novináři, management, rady, nebo politici? A existuje ještě prostor, jak tuhle „plíživou erozi“ zastavit dřív, než se stane nevratnou? Nejen o tom je tento rozhovor.

Comedian/neuroscientist Diya Basrai (@diyabasrai) joins Jesse, Andy and Matt to talk about Moravec's Paradox, whether there's something meat-specific about intelligence, a less-pessimistic AI take, a tool-using cow, Diya's comedy special and his comedy/science live show Uncontrolled Variables.

Koncesionářské poplatky by měly podle plánu vlády brzy skončit. Už od příštího ledna chce kabinet financovat ČT a rozhlas ze státního rozpočtu. Podrobnosti návrhu známé nejsou. Podaří se zachovat nezávislost veřejnoprávních médií?Hostem Ptám se já byl šéf divize Programu a digitálních služeb České televize Milan Fridrich. Vládní koalice ANO, SPD a Motoristů před dvěma týdny potvrdila svůj záměr na zrušení poplatků za televizi a rozhlas. Premiér Andrej Babiš (ANO) uvedl, že změnu očekává už od roku 2027. Česko se tak podle něj stane 18. zemí Evropské unie, která bude financovat veřejnoprávní média ze státního rozpočtu. Jak by to mělo konkrétně vypadat, ale ještě jasné není. Informace nemá ani nikdo z vrcholných představitelů České televize a Českého rozhlasu. Co nejdříve by se proto chtěli do debat o své budoucnosti zapojit. Obě média přitom chtějí bojovat za zachování současného systému financování, který jim zajišťuje potřebnou stabilitu a nezávislost. Jak řekl v pondělí v Ptám se já generální ředitel rozhlasu René Zavoral, pádné argumenty pro rušení poplatků podle něj zatím vůbec nepadly a stále proto vidí prostor rozhodnutí koalice zvrátit. Podobně to vnímá i druhý muž v čele České televize, ředitel Programu a digitálních služeb Milan Fridrich: „Budeme se snažit přesvědčit politiky o tom, aby to nebrali jako hotovou věc. Pracujeme s pětiletými plány programového a ekonomického rozvoje. Nedokážu si v tuhle chvíli představit, že by jiný model naplánoval to financování pět let dopředu.“„Víme, kolik lidí se na nás dívá. A oni budou chtít vědět, jestli ta kvalitní a robustní nabídka zůstane zachována a budou se mít na co dívat,“ uvedl Fridrich. V rozhovoru také komentoval, jak na image České televize negativně dopadá současný spor vedení zpravodajství s moderátorem Václavem Moravcem. Ten dlouhodobě odmítá pozvat do svého pořadu Otázky Václava Moravce šéfa koaliční SPD a předsedu Sněmovny Tomia Okamuru. „Myslím, že by zpravodajství mělo co nejrychleji tuhle kauzu uzavřít a dojít k nějakému řešení, které bude přijatelné pro obě strany. Protože je to hnisající rána, která nedělá České televize úplně image,“ prohlásil Fridrich s tím, že to ale neznamená, že by měl Moravec nebo jeho pořad končit. „Nikdo nechce ubližovat Václavu Moravcovi. Kromě zvaní Tomia Okamura nemá Václav Moravec žádný problém.“Kdo a kde připravuje nové mediální zákony? Čeká tuzemská veřejnoprávní média slovenská budoucnost? A chystají lidé v televizi stávku?--Podcast Ptám se já. Rozhovory s lidmi, kteří mají vliv, odpovědnost, informace.Sledujte na Seznam Zprávách, poslouchejte na Podcasty.cz a ve všech podcastových aplikacích.Archiv všech dílů najdete tady. Své postřehy, připomínky nebo tipy nám pište prostřednictvím sociálních sítí pod hashtagem #ptamseja nebo na e-mail: audio@sz.cz.

Ken and Preston examine whether robotics has lost its way, echoing Rodney Brooks' concerns. They dissect the gap between AI language models and physical robotics, focusing on dexterous manipulation, tactile sensing, and visual feedback. IN THIS EPISODE YOU'LL LEARN: 00:00:00 - Intro 00:02:37 - Why Ken agrees that robotics may have “lost its way” 00:03:37 - The critical gap between AI language skills and robotic manipulation 00:04:33 - How robot mobility is advancing, but dexterity still lags 00:08:15 - Why tying shoelaces is still too complex for robots 00:12:37 - The role of tactile sensing vs. vision in robotic surgery 00:14:45 - How camera placement in robotic hands affects manipulation 00:20:18 - Why the robot data gap could be 100,000 years behind language models 00:25:13 - Why simpler grippers often outperform human-like robotic hands 00:27:03 - The engineering behind Dex-Net and Ambi Robotics' success 00:34:37 - How real-world testing exposed unexpected robotic limitations Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Official website: Ken Goldberg. Website mentioned: Ambi Robotics.  Research Article: Dex-Net in Science Robotics January 2019. Executive Education profile: Prof. Ken Goldberg.  Ken Goldberg interview by Kara Manke: Are We Truly on the Verge of the Humanoid Robot Revolution?   Goldberg on Moravec's Paradox. Goldberg on AI and Creativity. TEDx Talk: "Robots:  What's Taking So Long?" Op-Ed by Ken Goldberg, Boston Globe: Let's Give AI a Chance. Research Papers are available for download. Related⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ books⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ mentioned in the podcast. Ad-free episodes on our⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Premium Feed⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. NEW TO THE SHOW? Join the exclusive ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TIP Mastermind Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to engage in meaningful stock investing discussions with Stig, Clay, Kyle, and the other community members. Follow our official social media accounts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X (Twitter)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Check out our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bitcoin Fundamentals Starter Packs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Browse through all our episodes (complete with transcripts) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Try our tool for picking stock winners and managing our portfolios: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TIP Finance Tool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Enjoy exclusive perks from our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠favorite Apps and Services⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Get smarter about valuing businesses in just a few minutes each week through our newsletter, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Intrinsic Value Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn how to better start, manage, and grow your business with the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠best business podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. SPONSORS Support our free podcast by supporting our sponsors: Simple Mining Linkedin Talent Solutions HardBlock Alexa+ Unchained Amazon Ads Vanta Shopify Abundant Mines Horizon Public.com - see the full disclaimer here. References to any third-party products, services, or advertisers do not constitute endorsements, and The Investor's Podcast Network is not responsible for any claims made by them. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm

Eva Hallman interviews Indy Fuel forward Brett Moravec prior to the Nov. 15, 2025 game vs. Rapid City.

In this episode of Chamber Chat, host Brandon Burton speaks with Dave Moravec, president of the Coleraine Chamber of Commerce. They discuss Dave's journey into the chamber world, his experiences as a leader, and the innovative strategies he has implemented to foster growth and engagement within the chamber. A significant focus is placed on the concept of the 'chamber flywheel,' which emphasizes attracting, engaging, and delighting members to create a sustainable and thriving community. Additionally, Dave shares insights from his upcoming book, 'Echoes Across the Tracks,' and offers valuable tips for chamber professionals looking to enhance their organizations. Transcript and show notes found at chamberchatpodcast.com/episode354. Please support this podcast by supporting our sponsors. Community Matters, Inc. chamberchatpodcast.com/podcast App My Community appmycommunity.com/chamberchat Resource Development Group rdgfundraising.com Econ Dev Ops econdevops.com Swypit chamberchatpodcast.com/cc  

Původně žurnalista, nyní režisér a scenárista Ondřej Moravec je průkopníkem virtuální reality v České republice. Jsou žurnalistika a virtuální realita světy, které se dají spojit? „Určitě. Na poli virtuální reality je silná dokumentaristická linie. Cílem zpravodajství, dokumentaristiky, je přinést realitu co nejblíž publiku. A to ta virtuální realita dokáže zprostředkovat opravdu dobře,“ popisuje Ondřej Moravec.Všechny díly podcastu Host Lucie Výborné můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Původně žurnalista, nyní režisér a scenárista Ondřej Moravec je průkopníkem virtuální reality v České republice. Jsou žurnalistika a virtuální realita světy, které se dají spojit? „Určitě. Na poli virtuální reality je silná dokumentaristická linie. Cílem zpravodajství, dokumentaristiky, je přinést realitu co nejblíž publiku. A to ta virtuální realita dokáže zprostředkovat opravdu dobře,“ popisuje Ondřej Moravec.

Jim talks with Nate Soares about the ideas in his and Eliezer Yudkowsky's book If Anybody Builds It, Everybody Dies: Why Superhuman AI Would Kill Us All. They discuss the book's claim that mitigating existential AI risk should be a top global priority, the idea that LLMs are grown, the opacity of deep learning networks, the Golden Gate activation vector, whether our understanding of deep learning networks might improve enough to prevent catastrophe, goodness as a narrow target, the alignment problem, the problem of pointing minds, whether LLMs are just stochastic parrots, why predicting a corpus often requires more mental machinery than creating a corpus, depth & generalization of skills, wanting as an effective strategy, goal orientation, limitations of training goal pursuit, transient limitations of current AI, protein folding and AlphaFold, the riskiness of automating alignment research, the correlation between capability and more coherent drives, why the authors anchored their argument on transformers & LLMs, the inversion of Moravec's paradox, the geopolitical multipolar trap, making world leaders aware of the issues, a treaty to ban the race to superintelligence, the specific terms of the proposed treaty, a comparison with banning uranium enrichment, why Jim tentatively thinks this proposal is a mistake, a priesthood of the power supply, whether attention is a zero-sum game, and much more. Episode Transcript "Psyop or Insanity or ...? Peter Thiel, the Antichrist, and Our Collapsing Epistemic Commons," by Jim Rutt "On Targeted Manipulation and Deception when Optimizing LLMs for User Feedback," by Marcus Williams et al. Attention Sinks and Compression Valleys in LLMs are Two Sides of the Same Coin," by Enrique Queipo-de-Llano et al. JRS EP 217 - Ben Goertzel on a New Framework for AGI "A Tentative Draft of a Treaty, With Annotations" Nate Soares is the President of the Machine Intelligence Research Institute. He has been working in the field for over a decade, after previous experience at Microsoft and Google. Soares is the author of a large body of technical and semi-technical writing on AI alignment, including foundational work on value learning, decision theory, and power-seeking incentives in smarter-than-human AIs.

At Viirtue Connect in Nashville, Jason Moravec, Senior Channel Account Manager at Xima Software, joined Doug Green, Publisher of Technology Reseller News, to discuss how Xima's advanced contact center solutions are helping MSPs expand revenue, strengthen customer relationships, and enhance user experience. Xima Software delivers cloud-based contact center and customer experience platforms designed to integrate seamlessly with leading UC systems like NetSapiens, which powers Viirtue and other Crexendo partners. “We focus on helping businesses communicate more effectively across every channel—voice, SMS, email, chat, and WhatsApp,” Moravec explained. “It's all about elevating the customer experience.” Through its integration with NetSapiens, Xima offers white-label, multi-channel contact center solutions that partners can brand as their own. The platform enhances standard UC capabilities with detailed analytics, cradle-to-grave reporting, and intelligent call routing—all designed to help MSPs deliver a premium service that customers can't easily replace. “Contact centers are incredibly sticky,” Moravec said. “When partners win the contact center, they often win the entire business. It's one of the most profitable and high-value parts of the UC ecosystem.” Xima also integrates AI and speech analytics to improve agent productivity and customer outcomes. From sentiment and tone detection to AI-powered chatbots and voice assistants, the platform uses automation to reduce call volume, speed up responses, and provide data-driven training insights. “Our AI isn't about replacing humans—it's about getting people to the right place faster and making agents more effective,” Moravec emphasized. For MSPs and Viirtue partners, Xima's solutions represent a powerful opportunity to differentiate, expand service offerings, and grow recurring revenue. To learn more about Xima Software, visit www.ximasoftware.com.

In this episode, Dave and Andrew dive into a work inspired by Shakespeare's The Tempest. Will the work live up to the Bard's reputation? And does this piece fit into the typical mold of a Pulitzer Prize winning work?    If you'd like more information about Paul Moravec, we recommend: Paul Moravec's personal website Dialogue with Moravec for the Kansas City Lyric Opera's production of The Shining Paul Moravec's short article “Tonality and Transcendence.” Contemporary Music Review vol. 6. no. 2 (1992): 39–42.

Jenže i ti se tu musejí nejdřív zaučit. Kdo je trénuje? - Uherské Hradiště bylo od dávných dob důležitou obchodní křižovatkou a lidé se tam usídlovali i přes opakující se záplavy. Jak se na ně adaptovali? - A jak zásadní byl pro československý odboj generál František Moravec? Hlavní strůjce plánu na atentát na Reinharda Heydricha se narodil přesně před 130 lety. Moderuje Daniela Vrbová.

In this engaging episode of Coffee & Tea with CarrieVee, CarrieVee welcomes back author, business leader, and master storyteller Dave Moravec for yet another insightful conversation. Dave shares the journey behind his newest book, Echoes to Remember, a sequel to his successful debut, Echoes Across the Tracks. Together, they explore the power of storytelling, time travel, and timeless principles of customer service that bridge both the past and the present.Dave offers a fascinating look into his fictional character Charlie—a seasoned business consultant who finds himself wrestling with the dilemma of whether to reveal his experiences of time travel. Through Charlie's adventures, Dave weaves powerful parables about business, leadership, and customer service. Notably, he challenges the traditional notion that “the customer is always right,” reframing it as “the customer is always the customer,” and shares real-life examples of how businesses can differentiate themselves through responsiveness and personal connection.Carrie and Dave discuss how customer expectations have evolved post-pandemic, touching on topics like service responsiveness, modern communication tools, and how old-school relationship-building lessons remain just as relevant today. Dave also teases future books in his “Echoes” series, from stories set at sea on cruise ships to tales inspired by the chaos of urban streets.Listeners will walk away reflecting on how personal experiences shape their choices, how to serve others more effectively in business and life, and how to translate the lessons of the past into meaningful action today.Writing Prompt: Dave encourages listeners to look back over significant life events—both triumphs and mistakes—and write about what they learned from those experiences, finding connections that shape who they've become today.Contact Dave Moravec:LinkedIn: https://www.linkedin.com/in/davemoravec2018/Email: ddmoravec5@gmail.comWebsite: www.salesmanagerforrent.comPhone: 309.838.1947 Echoes Across the Tracks Book: https://amzn.to/3UAnpcSEchoes to Remember Book: https://amzn.to/40fAKLa Echoes to Remember Coffee and Tea With CarrieVee Podcast Episode: https://podcasts.apple.com/us/podcast/coffee-and-tea-with-carrievee/id1514671446?i=1000654785238  Radical Empowerment Method Book on Amazon: https://amzn.to/3Bdp2BC Book CarrieVee for a Speaking Engagement: https://www.coachcarriev.com/contact-me Join the Confidence and Clarity Membership! https://carrievee.com/confidence-clarity-1 Schedule your Discovery Call with CarrieVee!https://schedulewithcarrievee.as.me/?appointmentType=12343596  Step Into Your Big Life Freebie: https://www.coachcarriev.com/stepintoyourbiglifefreebie The Radical Empowerment Method 2.0 Online Course https://www.coachcarriev.com/radicalempowermentmethod2  Get to an EVENT! www.carrievee.com/events Con

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

In this episode, therapist Becca shares her personal and professional journey from being immersed in diet culture to discovering intuitive eating and the Health at Every Size approach. She discusses the moment she realized she had an eating disorder, how working with a coach transformed her perspective, and her ongoing process of recovery. Becca and host Cristina explore the myths around eating disorder recovery, emphasizing that while triggers can reappear, long-term healing is possible. The conversation also delves into how personality frameworks like the Enneagram can help individuals understand their motivations and patterns related to disordered eating, offering additional tools for self-compassion and growth.SHOW NOTES: Click hereFollow me on Instagram: https://www.instagram.com/behind_the_bite

In this episode, I'm interviewing Exercise Physiology expert Emily Moravec (@Illustratedemily) who's turned her professional knowledge into a thriving Etsy business. Emily leveraged her expertise and scientific illustrations to create digital exercise guides, generating $3k+ in monthly semi-passive income. Tune in for an inspiring story and actionable insights on building a successful Etsy shop with niche digital products! **“How to Sell Your Stuff on Etsy” is not affiliated with or endorsed by Etsy.com    STUFF I MENTIONED:  ⭐FREE Mastering Etsy Ads Course:  https://www.howtosellyourstuff.com/request-etsy-ads-masterclass